MedTrace Logo

Clozapine Versus Haloperidol for Treating the First Episode of Schizophrenia

NCT00169091 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2015-04-07

No results posted yet for this study

Summary

This study will examine the physical responses brought on by clozapine and haloperidol in people experiencing their first episode of schizophrenia.

Conditions

Interventions

DRUG

Clozapine

Medication will be divided into twice daily dosing and administered in a blinded fashion. The medication will be tapered from 12.5 mg on Day 1 to up to 300 mg on Day 12.

DRUG

Haloperidol

Medication will be divided into twice daily dosing and administered in a blinded fashion. The medication will be tapered from 2 mg on Day 1 to up to 12 mg on Day 12.

Sponsors & Collaborators

  • National Institute of Mental Health (NIMH)

    collaborator NIH

  • Dartmouth-Hitchcock Medical Center

    collaborator OTHER

  • Commonwealth Research Center, Massachusetts

    collaborator OTHER

  • Novartis

    collaborator INDUSTRY

  • Harvard Medical School (HMS and HSDM)

    lead OTHER

Principal Investigators

  • Alan I Green, MD · Harvard Medical School (HMS and HSDM)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1996-03-31
Primary Completion
2003-09-30
Completion
2003-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00169091 on ClinicalTrials.gov